Improving preparedness to respond to cross-border hepatitis A outbreaks in the European Union/European Economic Area: towards comparable sequencing of hepatitis A virus.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
Jul 2019
Historique:
entrez: 18 7 2019
pubmed: 18 7 2019
medline: 17 7 2020
Statut: ppublish

Résumé

IntroductionSequence-based typing of hepatitis A virus (HAV) is important for outbreak detection, investigation and surveillance. In 2013, sequencing was central to resolving a large European Union (EU)-wide outbreak related to frozen berries. However, as the sequenced HAV genome regions were only partly comparable between countries, results were not always conclusive.AimThe objective was to gather information on HAV surveillance and sequencing in EU/European Economic Area (EEA) countries to find ways to harmonise their procedures, for improvement of cross-border outbreak responses.MethodsIn 2014, the European Centre for Disease Prevention and Control (ECDC) conducted a survey on HAV surveillance practices in EU/EEA countries. The survey enquired whether a referral system for confirming primary diagnostics of hepatitis A existed as well as a central collection/storage of hepatitis A cases' samples for typing. Questions on HAV sequencing procedures were also asked. Based on the results, an expert consultation proposed harmonised procedures for cross-border outbreak response, in particular regarding sequencing. In 2016, a follow-up survey assessed uptake of suggested methods.ResultsOf 31 EU/EEA countries, 23 (2014) and 27 (2016) participated. Numbers of countries with central collection and storage of HAV positive samples and of those performing sequencing increased from 12 to 15 and 12 to 14 respectively in 2016, with all countries typing an overlapping fragment of 218 nt. However, variation existed in the sequenced genomic regions and their lengths.ConclusionsWhile HAV sequences in EU/EEA countries are comparable for surveillance, collaboration in sharing and comparing these can be further strengthened.

Identifiants

pubmed: 31311618
doi: 10.2807/1560-7917.ES.2019.24.28.1800397
pmc: PMC6636214
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Références

J Virol. 2002 Sep;76(18):9516-25
pubmed: 12186933
J Gen Virol. 1992 Jun;73 ( Pt 6):1365-77
pubmed: 1318940
Vaccine. 1992;10 Suppl 1:S40-4
pubmed: 1335657
J Gen Virol. 2003 Dec;84(Pt 12):3191-201
pubmed: 14645901
J Virol. 2008 Feb;82(4):1688-700
pubmed: 18057242
Intervirology. 2010;53(1):15-9
pubmed: 20068336
J Clin Microbiol. 2010 Sep;48(9):3306-15
pubmed: 20592136
Vaccine. 2010 Sep 24;28(41):6653-7
pubmed: 20723630
Wkly Epidemiol Rec. 2012 Jul 13;87(28/29):261–76
pubmed: 22905367
Euro Surveill. 2013 Apr 25;18(17):20468
pubmed: 23647624
Euro Surveill. 2013 Jul 04;18(27):null
pubmed: 23870076
PLoS One. 2013 Sep 17;8(9):e74752
pubmed: 24069343
PLoS One. 2013 Nov 06;8(11):e74546
pubmed: 24223112
Emerg Infect Dis. 2014 Apr;20(4):596-602
pubmed: 24655539
J Virol. 1989 Nov;63(11):4932-7
pubmed: 2552172
Euro Surveill. 2015 Jan 29;20(4):null
pubmed: 25655054
Euro Surveill. 2015 Jul 23;20(29):21192
pubmed: 26227370
PLoS One. 2016 Feb 22;11(2):e0149642
pubmed: 26901877
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
Euro Surveill. 2017 Jan 26;22(4):
pubmed: 28181904
Euro Surveill. 2017 Feb 2;22(5):
pubmed: 28183391
Euro Surveill. 2017 Feb 2;22(5):
pubmed: 28183392
Euro Surveill. 2017 Feb 23;22(8):
pubmed: 28251892
Lancet Infect Dis. 2017 Oct;17(10):e306-e319
pubmed: 28645862
BMC Infect Dis. 2017 Jul 14;17(1):497
pubmed: 28705178
Euro Surveill. 2017 Jul 20;22(29):null
pubmed: 28749336
MMWR Morb Mortal Wkly Rep. 2017 Sep 22;66(37):999-1000
pubmed: 28934181
Euro Surveill. 2018 Mar;23(9):
pubmed: 29510780
Euro Surveill. 2018 May;23(22):null
pubmed: 29871720
Euro Surveill. 2018 Aug;23(33):
pubmed: 30131095
Euro Surveill. 2018 Sep;23(37):null
pubmed: 30229723
Euro Surveill. 2018 Oct;23(41):null
pubmed: 30326994

Auteurs

Theresa Enkirch (T)

Public Health Agency of Sweden, Solna, Sweden.
European Programme for Public Health Microbiology Training (EUPHEM), European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.

Ettore Severi (E)

European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.
Karolinska Institutet, Stockholm, Sweden.

Harry Vennema (H)

National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Lelia Thornton (L)

HSE - Health Protection Surveillance Centre, Dublin, Ireland.

Jonathan Dean (J)

National Virus Reference Laboratory, Dublin, Ireland.

Maria-Louise Borg (ML)

Ministry of Health, Msida, Malta.

Anna Rita Ciccaglione (AR)

National Institute of Health, Rome, Italy.

Roberto Bruni (R)

National Institute of Health, Rome, Italy.

Iva Christova (I)

National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.

Siew Lin Ngui (SL)

Public Health England (PHE), London, United Kingdom.

Koye Balogun (K)

Public Health England (PHE), London, United Kingdom.

Vratislav Němeček (V)

National Institute of Public Health, Prague, Czech Republic.

Mia Kontio (M)

National Institute for Health and Welfare (THL), Helsinki, Finland.

Mária Takács (M)

National Public Health Institute, Budapest, Hungary.

Andrea Hettmann (A)

National Public Health Institute, Budapest, Hungary.

Rita Korotinska (R)

Centre for Disease Prevention and Control, Riga, Latvia.

Arthur Löve (A)

Landspitali- National University Hospital, Reykjavik, Iceland.

Ana Avellón (A)

Carlos III Institute of Health, Madrid, Spain.

Milagros Muñoz-Chimeno (M)

Carlos III Institute of Health, Madrid, Spain.

Rita de Sousa (R)

National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal.

Denisa Janta (D)

National Institute of Public Health, Bucharest, Romania.

Jevgenia Epštein (J)

Health Board, Tallinn, Estonia.

Sofieke Klamer (S)

Scientific Institute of Public Health, Brussels, Belgium.

Vanessa Suin (V)

Sciensano, Directorate Infectious diseases in humans, Brussels, Belgium.

Stephan W Aberle (SW)

Center for Virology, Medical University of Vienna, Vienna, Austria.

Heidemarie Holzmann (H)

Center for Virology, Medical University of Vienna, Vienna, Austria.

Kassiani Mellou (K)

Hellenic Centre for Disease Control and Prevention, Athens, Greece.

Josefine Lundberg Ederth (JL)

Public Health Agency of Sweden, Solna, Sweden.

Lena Sundqvist (L)

Public Health Agency of Sweden, Solna, Sweden.

Anne-Marie Roque-Afonso (AM)

National Reference Centre for Hepatitis A, Villejuif, France.

Sanja Kurečić Filipović (SK)

Croatian Institute of Public Health, Zagreb, Croatia.

Mario Poljak (M)

Institute of Microbiology and Immunology, Ljubljana, Slovenia.

Line Vold (L)

Norwegian institute of Public Health, Oslo, Norway.

Kathrine Stene-Johansen (K)

Norwegian institute of Public Health, Oslo, Norway.

Sofie Midgley (S)

Statens Serum Institut (SSI), Copenhagen, Denmark.

Thea Kølsen Fischer (TK)

Statens Serum Institut (SSI), Copenhagen, Denmark.
Department of Infectious Diseases and Global Health, University of Southern Denmark, Odense, Denmark.

Mirko Faber (M)

Robert Koch Institute (RKI), Berlin, Germany.

Jürgen J Wenzel (JJ)

National Reference Laboratory for HAV, Regensburg University Medical Center, Regensburg, Germany.

Johanna Takkinen (J)

European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.

Katrin Leitmeyer (K)

European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH